Loading…
Danaher Corp
Danaher Corp (DHR) is listed on NYSE and classified in Diagnostics & Research, part of the Healthcare sector. It is headquartered in Washington, United States and has 58,000 employees. The company is worth $161.51B and trades at 38.7x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was $24.57B in fiscal 2025, up 2.9% from the year before. Net income was $3.61B. The share price is 5.4% below its 52-week high of $242.80. It pays a dividend yielding 0.70%, and has raised its annual dividend for 12 years in a row in our records. 13 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Cliff Asness (AQR Capital Management), at $503.2M. In that quarter, 6 of them opened or added to the position and 4 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Articles on this site that cover Danaher Corp.
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Major managers that reported this stock in their latest 13F.
▼ -19.7% over 5Y.
today you would have $850.08▼ -15.0%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 19 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Year-end price | $228.92 | $229.55 | $231.34 | $235.30 | $291.68 | $196.93 | $136.06 | $91.42 | $82.29 | $69.01 | $62.43 | $57.61 | $51.89 | $37.57 | $31.62 | $31.70 | $25.27 |
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Median P/E of 24.3 among peers in the sector.
Median P/E of 21.7 across this company’s own years on record.
Cash flow growing 3.1% a year for 10 years, discounted at 10%, then 2.5% forever.
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ISRGIntuitive Surgical Inc | $443.85 | 53.7x | 9.6x | 0.00% | 17.93% | $156.8B |
| PFEPfizer Inc | $30.42 | 40.0x | 2.0x | 5.65% | 5.01% | $173.38B |
| NVONovo Nordisk A S | $39.43 | 9.6x | 5.3x | 4.57% | 59.81% | $174.01B |
| ABTAbbott Laboratories | $102.51 |
| $19.02 |
| $29.49 |
| P/E | 21.7x | 45.3x | 43.4x | 36.3x | 24.4x | 33.9x | 45.4x | 37.9x | 27.6x | 26.3x | 21.3x | 14.9x | 17.9x | 20.3x | 16.6x | 15.1x | 17.9x | 21.7x | 14.3x | 20.9x |
| P/S | 4.2x | 6.6x | 6.9x | 7.2x | 7.3x | 9.5x | 7.1x | 6.0x | 4.2x | 4.2x | 3.2x | 4.4x | 4.7x | 2.9x | 2.1x | 2.0x | 2.5x | 2.4x | 1.4x | 2.6x |
| P/B | 2.6x | 3.1x | 3.3x | 3.2x | 3.9x | 5.2x | 4.0x | 3.5x | 2.6x | 2.5x | 2.3x | 2.7x | 2.6x | 2.4x | 2.0x | 1.9x | 2.3x | 2.1x | 1.8x | — |
| EPS | $5.05 | $5.29 | $6.38 | $9.66 | $8.61 | $4.34 | $3.59 | $3.32 | $3.13 | $3.24 | $4.20 | $3.22 | $2.55 | $2.26 | $2.09 | $1.77 | $1.16 | $1.33 | $1.41 |
| Dividend yield | 0.38% | 0.56% | 0.47% | 0.43% | 0.38% | 0.26% | 0.32% | 0.44% | 0.62% | 0.60% | 0.63% | 0.58% | 0.47% | 0.13% | 0.18% | 0.19% | 0.17% | 0.17% | 0.21% | 0.13% |
| Payout | 8.65% | 25.35% | 20.42% | 15.50% | 9.18% | 8.65% | 14.72% | 16.79% | 17.11% | 15.86% | 13.50% | 8.64% | 8.35% | 2.63% | 2.98% | 2.89% | 3.03% | 3.76% | 3.03% | 2.63% |
| Profit margin | 15.55% | 14.71% | 16.33% | 19.94% | 27.06% | 25.94% | 16.36% | 16.79% | 15.55% | 16.06% | 15.13% | 23.26% | 20.19% | 14.74% | 13.10% | 13.50% | 14.29% | 10.95% | 10.38% | 12.42% |
| ROE | 11.11% | 6.88% | 7.87% | 8.91% | 14.39% | 14.24% | 9.17% | 9.94% | 9.40% | 9.45% | 11.10% | 14.17% | 11.11% | 12.04% | 12.58% | 12.85% | 13.08% | 9.90% | 13.43% | — |
Median of the years shown; P/E years above 200x are left out.
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
5 methods answered, across 3 families.
Room for errors in the reported numbers.
-56.5% from the average.
Models, not forecasts, and not investment advice. How each formula works →
| 37.4x |
| 3.4x |
| 2.46% |
| — |
| $177.38B |
| VRTXVertex Pharmaceuticals Inc | $535.17 | 31.0x | 6.7x | 0.00% | 23.54% | $135.64B |
| GILDGilead Sciences Inc | $157.19 | — | 16.5x | 2.09% | -20.68% | $194.91B |
